Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Bivalirudin in Acute Myocardial Infarction
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 380
- Registration Number
- NCT02897037
- Locations
- 🇨🇳
Department of Cardiology，General Hospital of Shenyang Military Region, Shanyang, Liaoning, China
Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 76
- Registration Number
- NCT02860299
- Locations
- 🇫🇷
CHU Dijon Bourgogne, Dijon, France
Randomized Anticoagulation Trial in Opcab (RATIO)
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Azienda Ospedaliera di Lecco
- Target Recruit Count
- 900
- Registration Number
- NCT02812355
- Locations
- 🇨🇳
Jilin Heart Hospital, Changchun, Jilin, China
🇮🇹ASST Lecco, Lecco, Italy
🇮🇹Azienda Ospedaliera Universitaria di Sassari, Sassari, Italy
Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 1770
- Registration Number
- NCT02787317
- Locations
- 🇨🇳
ChinaPLAGH, Beijing, Beijing, China
Radial Artery Occlusion After Endovascular Procedure
- Conditions
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Azienda Sanitaria ULSS 13 Dolo, Mirano
- Target Recruit Count
- 2168
- Registration Number
- NCT02762344
- Locations
- 🇮🇹
Ospedale Civile, Mirano, Italy
Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 50
- Registration Number
- NCT02755818
Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set
- Conditions
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 24
- Registration Number
- NCT02687256
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Ziekenhuis Oost-Limburg
- Target Recruit Count
- 75
- Registration Number
- NCT02674906
- Locations
- 🇧🇪
Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium
Investigating Different Anticoagulants for Renal Replacement Therapy
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 638
- Registration Number
- NCT02669589
- Locations
- 🇩🇪
University Hospital Aachen, Aachen, Germany
🇩🇪Klinikum Augsburg, Augsburg, Germany
🇩🇪HELIOS Klinikum Bad Saarow, Dept. of Intensive Care, Bad Saarow, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.